Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 1;204(3):371-372.
doi: 10.1164/rccm.202103-0682LE.

Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease

Stephanie L Kuek  1 , Sarath C Ranganathan  1   2   3 , Joanne Harrison  1   2   3 , Philip J Robinson  1   2   3 , Shivanthan Shanthikumar  1   2   3
Affiliations
Comment

Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease

Stephanie L Kuek et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Burgel P-R, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. French Cystic Fibrosis Reference Network Study Group. Rapid improvement after starting elexacaftor–tezacaftor–ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med. 2021;204 - PubMed
    1. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940–1948. - PMC - PubMed
    1. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809–1819. - PMC - PubMed
    1. Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and 1 or more F508del alleles: Interim results of an open-label phase 3 clinical trial. Am J Respir Crit Care Med. 2021;203:381–385. - PMC - PubMed
    1. Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, et al. CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019;18:321–333. - PMC - PubMed